Semaglutide as a Renoprotective Metabolic Modulator in Diabetic Nephropathy: An Expanded Case Series from West Bengal, India

Abstract

Diabetic nephropathy remains one of the most significant etiological drivers of chronic kidney disease and end-stage renal failure worldwide, with a particularly rising burden in developing regions such as India. Semaglutide, a glucagon-like peptide-1 receptor agonist, has recently emerged as a multifunctional therapeutic agent exhibiting glycemic, cardiovascular, and potential renoprotective effects beyond conventional metabolic control. This case series evaluates the effect of semaglutide on urine albumin-creatinine ratio (UACR) and glycemic indices in non- obese patients with diabetic nephropathy from West Bengal, India. Eighteen patients were observed over a study period from November 2025 to March 202C, receiving semaglutide 0.5 mg subcutaneously once weekly for three months as an adjunct to standard therapy.
Comparative evaluation of baseline and follow-up parameters demonstrated a consistent reduction in albuminuria, with mean UACR declining from 418 mg/g to 252 mg/g, representing an approximate 3U.7% reduction. Mean HbA1c improved from 8.72% to 7.18% over the same period. These findings reinforce the potential role of semaglutide as a reno-metabolic modulator in diabetic kidney disease.